2012-06-01
Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy
Publication
Publication
Clinical Pharmacology and Therapeutics , Volume 91 - Issue 6 p. 1022- 1026
ABCC2 (MRP2, cMOAT) expression has been implicated in cisplatin resistance in vitro. In mice, cisplatin disposition and toxicity were unaffected by Abcc2 knockout (Abcc2-/-). Moreover, in cancer patients (n = 237), cisplatin pharmacokinetics (P > 0.12) and efficacy (P > 0.41) were not associated with seven of the single-nucleotide polymorphisms (SNPs) in ABCC2. These SNPs were also not correlated with ABCC2 expression in the NCI60 panel (P > 0.26) or with cisplatin-induced cytotoxicity (P = 0.21). These findings highlight the importance of verifying drug-transporter interactions with in vitro tests in humans.
| Additional Metadata | |
|---|---|
| doi.org/10.1038/clpt.2011.330, hdl.handle.net/1765/55371 | |
| Clinical Pharmacology and Therapeutics | |
| Organisation | Department of Medical Oncology |
|
Sprowl, J., Gregorc, V., Lazzari, L., Mathijssen, R., Loos, W., & Sparreboom, A. (2012). Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy. Clinical Pharmacology and Therapeutics, 91(6), 1022–1026. doi:10.1038/clpt.2011.330 |
|